NEW YORK, Dec. 3 (GenomeWeb News) - Shares in Genaissance Pharmaceuticals were up 7.64 percent at $1.69 in mid-afternoon trading one day after the company announced an animal-genotyping collaboration with a British company.
Yesterday, Genaissance said it will use its HAP technology platform perform genotyping studies on three undisclosed meat animal species provided by Sygen International.
UK-based Sygen is an animal-breeding concern, which has two subsidiaries. One provides breeding stock to the North American pork industry, and the other supplies shrimp for cultivation.
Terms of the agreement were not disclosed.